Imetelstat in Patients with Lower-Risk Myelodysplastic Syndromes Who Have Relapsed or Are Refractory to Erythropoiesis-Stimulating Agents (IMerge): A Multinational, Randomised, Double-Blind, Placebo-Controlled, Phase III Trial

Patients (aged ≥18 years) with erythropoiesis-stimulating agents (ESA)-relapsed, ESA-refractory, or ESA-ineligible lower-risk myelodysplastic syndromes were randomly assigned via a computer-generated schedule to receive imetelstat 7·5 mg/kg or placebo.